Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus in advanced hepatocellular carcinoma with Child-Pugh B cirrhosis
2009-014443-36Phase 2Terminated
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in hepatocellular carcinoma (HCC), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Disease control rate at 3 months. Started Sep 2009; status: terminated.
02
Drugs
temsirolimus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2009-014443-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014443-36.